ArticleBMJ open2022

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial.

Qian Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.